Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus
- PMID: 15168797
- DOI: 10.1016/j.antiviral.2003.09.008
Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus
Abstract
We obtained two mutant strains of respiratory syncytial virus (RSV) which showed resistance against NMSO3 after 15 and 33 passages, respectively, in HEp-2 cells in the presence of 6.8 microM of NMSO3. The EC50 values of NMSO3 for the resistant virus strains were 0.48 and 0.93 microM, that is 4.8-9.3 times higher than that of the parent strain (EC50 = 0.1 microM). The most resistant strain also showed resistance against heparin but was sensitive to dextran sulfate and a polyoxotungstate, PM-523. In order to determine whether the acquisition of resistance to NMSO3 was the result of the accumulation of genetic changes of virus, we sequenced the G- and F-protein genes. In comparison with the standard type of RSV strains, we identified changes of 10 amino acids in the G protein including those at the central conserved segment. However, we did not observe any particular changes in the amino acid sequence of the F-protein of the resistant strains. From these results, we conclude that NMSO3 inhibits the G-protein interaction to the receptor. The mutations in the G-protein may result in the observed phenotypic resistance of RSV towards NMSO3.
Similar articles
-
Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays.Antiviral Res. 2004 Jul;63(1):51-9. doi: 10.1016/j.antiviral.2004.02.006. Antiviral Res. 2004. PMID: 15196820
-
YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action.Antiviral Res. 2005 Feb;65(2):125-31. doi: 10.1016/j.antiviral.2004.12.002. Antiviral Res. 2005. PMID: 15708639
-
Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo.Antiviral Res. 2000 Jul;47(1):41-51. doi: 10.1016/s0166-3542(00)00091-7. Antiviral Res. 2000. PMID: 10930645
-
Antiviral activity of NMSO3 against adenovirus in vitro.Antiviral Res. 2001 Dec;52(3):281-8. doi: 10.1016/s0166-3542(01)00167-x. Antiviral Res. 2001. PMID: 11675145
-
Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses.J Antimicrob Chemother. 2004 Aug;54(2):299-302. doi: 10.1093/jac/dkh355. Epub 2004 Jul 14. J Antimicrob Chemother. 2004. PMID: 15254023 Review.
Cited by
-
Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide.Antimicrob Agents Chemother. 2012 Oct;56(10):5278-88. doi: 10.1128/AAC.00771-12. Epub 2012 Jul 30. Antimicrob Agents Chemother. 2012. PMID: 22850525 Free PMC article.
-
Viral load drives disease in humans experimentally infected with respiratory syncytial virus.Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14. doi: 10.1164/rccm.201002-0221OC. Epub 2010 Jul 9. Am J Respir Crit Care Med. 2010. PMID: 20622030 Free PMC article. Clinical Trial.
-
Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection.Viruses. 2015 Feb 16;7(2):798-819. doi: 10.3390/v7020798. Viruses. 2015. PMID: 25690799 Free PMC article.
-
Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Viruses. 2018 Jan 21;10(1):48. doi: 10.3390/v10010048. Viruses. 2018. PMID: 29361733 Free PMC article. Review.
-
Circulation patterns and molecular epidemiology of human respiratory syncytial virus over five consecutive seasons in Morocco.Influenza Other Respir Viruses. 2023 Oct 17;17(10):e13203. doi: 10.1111/irv.13203. eCollection 2023 Oct. Influenza Other Respir Viruses. 2023. PMID: 37859975 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources